MENU
+Compare
NTLA
Stock ticker: NASDAQ
AS OF
Aug 11, 11:54 AM (EDT)
Price
$10.79
Change
+$0.01 (+0.09%)
Capitalization
1.16B

NTLA Intellia Therapeutics Forecast, Technical & Fundamental Analysis

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics... Show more

Industry: #Biotechnology
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for NTLA with price predictions
Aug 08, 2025

NTLA's Stochastic Oscillator remains in oversold zone for 6 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 140 cases where NTLA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for NTLA moved out of overbought territory on July 24, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator moved out of overbought territory. In of the 18 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on July 31, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NTLA as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NTLA turned negative on July 29, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NTLA broke above its upper Bollinger Band on July 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.619) is normal, around the industry mean (18.662). P/E Ratio (0.000) is within average values for comparable stocks, (54.033). NTLA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.909). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (20.921) is also within normal values, averaging (286.048).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NTLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

NTLA is expected to report earnings to rise 1.67% to -99 cents per share on November 06

Intellia Therapeutics NTLA Stock Earnings Reports
Q3'25
Est.
$-1.00
Q2'25
Beat
by $0.05
Q1'25
Beat
by $0.17
Q4'24
Beat
by $0.07
Q3'24
Beat
by $0.05
The last earnings report on August 07 showed earnings per share of -98 cents, beating the estimate of -102 cents. With 569.74K shares outstanding, the current market capitalization sits at 1.16B.
A.I. Advisor
published General Information

General Information

a developer of proprietary, potentially curative therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
40 Erie Street
Phone
+1 857 285-6200
Employees
526
Web
https://www.intelliatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCAEX13.120.12
+0.92%
Fidelity Climate Action
FMDRX32.490.21
+0.65%
Franklin Mutual Global Discovery R6
LAVPX15.770.08
+0.51%
Lord Abbett Fundamental Equity P
HGHSX35.200.12
+0.34%
Hartford Healthcare R4
PPQPX7.85-0.08
-1.01%
Principal MidCap Growth III R5

NTLA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been loosely correlated with CRSP. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if NTLA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-5.85%
CRSP - NTLA
65%
Loosely correlated
-1.72%
BEAM - NTLA
65%
Loosely correlated
-1.34%
RXRX - NTLA
56%
Loosely correlated
-0.92%
IDYA - NTLA
53%
Loosely correlated
+3.08%
ABCL - NTLA
53%
Loosely correlated
+0.24%
More

Groups containing NTLA

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-5.85%
NTLA
(2 stocks)
80%
Closely correlated
+1.43%